Tyrosine Kinase Inhibitors

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

By

Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

By

Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

By

Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

By

Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

By

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

Patients Report Significant Fatigue with Sorafenib, Sunitinib in Renal Cell Carcinoma

Patients Report Significant Fatigue with Sorafenib, Sunitinib in Renal Cell Carcinoma

By

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

By

Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

By

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy

[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

By

Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

By

Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.

Kinase Inhibitors: Managing Side Effects in GI Cancers

Kinase Inhibitors: Managing Side Effects in GI Cancers

By

A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

By

Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

By

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.

Cabozantinib May Be More Effective in Patients With Certain Mutations

By

Patients with medullary thyroid cancer who harbor RET M918T or RAS mutations may derive greater clinical benefit from cabozantinib compared with patients who do not have those genetic mutations.

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

By

Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

By

Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

By

For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Data Confirm Benefit of Cobimetinib and Vemurafenib in Melanoma

By

Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

By

A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.

SRC Kinase Inhibitor Could Be a New Treatment for Breast Cancer

SRC Kinase Inhibitor Could Be a New Treatment for Breast Cancer

By

Scientists discovered the compound eCF506. This compound was more effective than existing medicines at targeting breast cancer cells because it more selectively inhibited SRC tyrosine kinase.

Treatment Compliance and Severe Adverse Events Limit the Use of Tyrosine Kinase Inhibitors in Refractory Thyroid Cancer

Treatment Compliance and Severe Adverse Events Limit the Use of Tyrosine Kinase Inhibitors in Refractory Thyroid Cancer

[OncoTargets and Therapy] This research examines patient compliance with tyrosine kinase inhibitor (TKI) treatment for refractory and progressive thyroid cancer, as well as exploring the efficacy and serious adverse events associated with this treatment.

Increased risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

Increased risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

[OncoTargets and Therapy] This research examines the risks and benefits associated with using small-molecule vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).

Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations

Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations

Afatinib is clinically active and well tolerated in many tyrosine kinase inhibitor (TKI)-pretreated patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations, according to a new study.

New tool uses drug spillover to match cancer patients with treatments

New tool uses drug spillover to match cancer patients with treatments

By

A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.

Profile of neratinib and its potential in the treatment of breast cancer

Profile of neratinib and its potential in the treatment of breast cancer

[Breast Cancer: Targets and Therapy] This research reviews the preclinical as well as clinical data on neratinib.

Use of Pharmacokinetics to Measure Response in CML

Use of Pharmacokinetics to Measure Response in CML

By

What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side effects in patients

By

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs